Techniques of Postmarketing Surveillance

[1]  S. Shapiro.  The epidemiological evaluation of drugs. , 2009, Acta medica Scandinavica. Supplementum.

[2]  M. Vessey.  Case-control studies in the assessment of drug safety. , 2009, Acta medica Scandinavica. Supplementum.

[3]  R. Royer,et al.  ADVERSE DRUG REACTION MONITORING: DOING IT THE FRENCH WAY , 1985, The Lancet.

[4]  B. Strom,et al.  The computerized on‐line Medicaid pharmaceutical analysis and surveillance system: A new resource for postmarketing drug surveillance , 1985, Clinical pharmacology and therapeutics.

[5]  K. Strandberg.  Experiences from the Who Collaborating Centre for International Drug Monitoring , 1985 .

[6]  B. Vrhovac,et al.  Panel on Management of ADR Reports in Selected National Centers , 1985 .

[7]  J. Laporte.  Developing National Systems: Spain as a Model , 1985 .

[8]  A. Soffer.  The practitioner's role in detection of adverse drug reactions. , 1984, Archives of internal medicine.

[9]  O S Miettinen,et al.  Post-marketing studies of drug efficacy: why? , 1984, The American journal of medicine.

[10]  T. Humphries,et al.  A unique postmarket outpatient surveillance program of cimetidine: report on phase II and final summary. , 1984, The American journal of gastroenterology.

[11]  P. Turner.  FOOD AND DRUGS: WHY DIFFERENT APPROACHES TO THEIR SAFETY? , 1984, The Lancet.

[12]  A. Stergachis,et al.  Postmarketing Follow‐up at Group Health Cooperative of Puget Sound , 1984, Pharmacotherapy.

[13]  W. Inman.  Prescription-event monitoring. A preliminary study of benoxaprofen and fenbufen. , 1984, Acta medica Scandinavica. Supplementum.

[14]  O. Miettinen,et al.  Postmarketing studies of drug efficacy: When must they be randomized? , 1983, Clinical pharmacology and therapeutics.

[15]  L. Lasagna.  Discovering adverse drug reactions. , 1983, JAMA.

[16]  D E Knapp,et al.  Discovery of adverse drug reactions. A comparison of selected phase IV studies with spontaneous reporting methods. , 1983, JAMA.

[17]  W. Inman.  Adverse reactions to new drugs , 1983, British medical journal.

[18]  G. Venning.  Identification of adverse reactions to new drugs. III: Alerting processes and early warning systems. , 1983, British medical journal.

[19]  G. Venning.  Identification of adverse reactions to new drugs. II (continued): How were 18 important adverse reactions discovered and with what delays? , 1983, British medical journal.

[20]  G. Venning.  Identification of adverse reactions to new drugs. I: What have been the important adverse reactions since thalidomide? , 1983, British medical journal.

[21]  E. Robert,et al.  MATERNAL VALPROIC ACID AND CONGENITAL NEURAL TUBE DEFECTS , 1982, The Lancet.

[22]  J. Venulet,et al.  How good are articles on adverse drug reactions? , 1982, British medical journal.

[23]  J. Schlesselman,et al.  Case-Control Studies: Design, Conduct, Analysis , 1982 .

[24]  W. Inman.  Postmarketing surveillance of adverse drug reactions in general practice. II: Prescription-event monitoring at the University of Southampton. , 1981, British medical journal.

[25]  R. Gralla,et al.  Comparison of methods of evaluating nephrotoxicity of cis‐platinum , 1980, Clinical pharmacology and therapeutics.

[26]  B. Strom,et al.  Can postmarketing surveillance help to effect optimal drug therapy? , 1979, JAMA.

[27]  H. Jick.  The Commission on Professional and Hospital Activities--Professional Activity Study. A national resource for the study of rare illnesses. , 1979, American journal of epidemiology.

[28]  M. Mitchell,et al.  PROSTAGLANDINS IN PATENT DUCTUS ARTERIOSUS , 1978, The Lancet.

[29]  Cohen Mr.  A compilation of abstracts and an index of articles published by the Boston Collaborative Drug Surveillance Program. , 1977 .

[30]  H. Jick.  The discovery of drug-induced illness. , 1977, The New England journal of medicine.

[31]  G. Volans.  Drug Effects in Hospitalized Patients , 1976 .

[32]  J. Schlesselman,et al.  Sample size requirements in cohort and case-control studies of disease. , 1974, American journal of epidemiology.

[33]  M. Lockshin,et al.  Letter: Lymphocyte response. , 1974, Lancet.

[34]  A. Herbst,et al.  Adenocarcinoma of the vagina. Association of maternal stilbestrol therapy with tumor appearance in young women. , 1971, The New England journal of medicine.

[35]  W. Inman,et al.  The Study of Adverse Reactions to Drugs [Abridged] , 1970 .

[36]  W HAENSZEL,et al.  Lung-cancer mortality as related to residence and smoking histories. I. White males. , 1962, Journal of the National Cancer Institute.

[37]  F. Colombo.  Epidemiological evaluation of drugs , 1977 .